A trial team from Quinn Emanuel Urquhart & Sullivan lands the first runner-up spot this week for scoring a double whammy in the latest patent battle over DNA sequencing patents. A Delaware federal jury awarded Quinn client Complete Genomics $333 million in damages last week, while also invalidating two patents asserted by competitor Illumina. Jurors further found Illumina’s infringement was willful, opening the door for U.S. District Judge Maryellen Noreika to potentially enhance damages by up to three times depending on her read of Illumina’s conduct. The Quinn team included partners David Bilsker, Andrew Bramhall, David Perlson and Anne Toker, and associates Margaret Shyr and Andrew Naravage.

Also landing runners-up honors this week are Matthew Ingber of Mayer Brown and Michael Martinez of Kramer Levin Naftalis & Frankel who secured a trial win against the U.S. Securities and Exchange Commission last week. After a weeklong trial, a Manhattan jury on Friday sided with their client, James Im, a former senior bond trader at Nomura Inc. who took the stand and admitted to lying to customers about the prices of commercial mortgage-backed securities. The jury found Im, who also testified that clients knew not to take traders at face value, hadn’t committed securities fraud.